Lipid metabolism US Medical PG Practice Questions and MCQs
Practice US Medical PG questions for Lipid metabolism. These multiple choice questions (MCQs) cover important concepts and help you prepare for your exams.
Lipid metabolism US Medical PG Question 1: A 15-year-old boy is brought to the emergency department by his parents because of lethargy, repeated vomiting, and abdominal pain for 6 hours. Over the past 2 weeks, he has reported increased urinary frequency to his parents that they attributed to his increased oral fluid intake. Examination shows dry mucous membranes and rapid, deep breathing. Laboratory studies show the presence of acetoacetate in the urine. Which of the following cells is unable to use this molecule for energy production?
- A. Myocyte
- B. Adipocyte
- C. Neuron
- D. Thrombocyte
- E. Hepatocyte (Correct Answer)
Lipid metabolism Explanation: ***Hepatocyte***
- **Hepatocytes** are the primary site of **ketone body synthesis** during fasting, starvation, or poorly controlled diabetes, producing acetoacetate and β-hydroxybutyrate from fatty acid oxidation.
- However, hepatocytes **cannot utilize ketone bodies for energy** because they lack the enzyme **succinyl-CoA:3-ketoacid CoA transferase (thiophorase)**, which is essential for converting acetoacetate to acetoacetyl-CoA.
- This enzymatic deficiency ensures that ketone bodies produced by the liver are exported to **peripheral tissues** (brain, muscle, kidney) for energy utilization during periods of glucose scarcity.
- This represents a critical metabolic concept: the liver makes ketones for other organs but cannot use them itself.
*Thrombocyte*
- **Thrombocytes** (platelets) lack **mitochondria** and rely exclusively on **anaerobic glycolysis** for ATP production.
- While platelets technically cannot use ketone bodies due to the absence of mitochondria, this is not the primary educational focus when discussing ketone body metabolism in biochemistry.
- Platelets also cannot perform oxidative phosphorylation or utilize fatty acids.
*Adipocyte*
- **Adipocytes** can utilize **acetoacetate** for energy, particularly during fasting states when ketone body levels are elevated.
- They possess mitochondria and the enzyme **succinyl-CoA:3-ketoacid CoA transferase**, allowing conversion of acetoacetate to acetoacetyl-CoA and subsequent entry into the citric acid cycle.
*Myocyte*
- **Myocytes** (cardiac and skeletal muscle) are major consumers of **ketone bodies** during prolonged fasting, starvation, or extended exercise.
- The heart preferentially uses ketone bodies over glucose when available, making them highly efficient at ketone body oxidation.
- Muscle cells contain all necessary enzymes to convert acetoacetate to acetyl-CoA for **oxidative phosphorylation**.
*Neuron*
- **Neurons** adapt to use **ketone bodies** as an alternative fuel to glucose during prolonged fasting (after 3-4 days), providing up to 60-70% of the brain's energy needs.
- This metabolic flexibility is crucial for survival during starvation and is the basis for therapeutic ketogenic diets in certain neurological conditions.
- Brain tissue efficiently metabolizes both acetoacetate and β-hydroxybutyrate.
Lipid metabolism US Medical PG Question 2: A 63-year-old man with high blood pressure, dyslipidemia, and diabetes presents to the clinic for routine follow-up. He has no current complaints and has been compliant with his chronic medications. His blood pressure is 132/87 mm Hg and his pulse is 75/min and regular. On physical examination, you notice that he has xanthelasmas on both of his eyelids. He currently uses a statin to lower his LDL but has not reached the LDL goal you have set for him. You would like to add an additional medication for LDL control. Of the following, which statement regarding fibrates is true?
- A. Fibrates inhibit the rate-limiting step in cholesterol synthesis
- B. Fibrates can potentiate the risk of myositis when given with statins (Correct Answer)
- C. Fibrates can cause significant skin flushing and pruritus
- D. Fibrates can increase the risk of cataracts
- E. The primary effect of fibrates is to lower LDL
Lipid metabolism Explanation: ***Fibrates can potentiate the risk of myositis when given with statins***
- **Fibrates** and **statins** can both independently cause muscle toxicity (myopathy, rhabdomyolysis).
- When used concomitantly, especially **gemfibrozil** with statins, there is an **increased risk of muscle adverse events** due to pharmacokinetic interactions that raise statin levels.
- This combination requires careful monitoring and is often avoided; **fenofibrate** is preferred over gemfibrozil when combination therapy is needed.
*Fibrates inhibit the rate-limiting step in cholesterol synthesis*
- This statement describes the mechanism of action of **statins**, which inhibit **HMG-CoA reductase**, the rate-limiting enzyme in cholesterol synthesis.
- Fibrates, on the other hand, act primarily by activating **PPAR-alpha receptors**, leading to altered lipid metabolism (increased lipoprotein lipase activity, decreased VLDL synthesis).
*Fibrates can cause significant skin flushing and pruritus*
- **Niacin (nicotinic acid)** is the lipid-modifying agent most commonly associated with significant **skin flushing and pruritus**, mediated by prostaglandin release.
- Fibrates do not cause significant flushing; their side effects include GI disturbances, gallstones, and potential muscle toxicity.
*Fibrates can increase the risk of cataracts*
- This is **not an established adverse effect** of the fibrate class.
- While **clofibrate** (an older, largely discontinued fibrate) showed some association with cataracts in older studies, this is not a recognized risk with modern fibrates like **fenofibrate** and **gemfibrozil**.
- Current fibrate therapy does not require routine ophthalmologic monitoring for cataracts.
*The primary effect of fibrates is to lower LDL*
- The primary effect of **fibrates** is to significantly **lower triglycerides** (by 30-50%) and **increase HDL cholesterol** levels (by 10-20%).
- While they can cause a modest decrease in LDL cholesterol (10-15%), this is not their primary or most pronounced lipid-modifying effect.
- Fibrates are primarily indicated for **hypertriglyceridemia** and mixed dyslipidemia.
Lipid metabolism US Medical PG Question 3: A 24-year-old man presents for an annual check-up. He is a bodybuilder and tells you he is on a protein-rich diet that only allows for minimal carbohydrate intake. His friend suggests he try exogenous glucagon to help him lose some excess weight before an upcoming competition. Which of the following effects of glucagon is he attempting to exploit?
- A. Increased glucose utilization by tissues
- B. Decreased blood cholesterol level
- C. Increased hepatic gluconeogenesis
- D. Increased lipolysis in adipose tissues (Correct Answer)
- E. Increased hepatic glycogenolysis
Lipid metabolism Explanation: ***Increased lipolysis in adipose tissues***
- While **glucagon's primary target is the liver**, it can have **modest lipolytic effects** on adipose tissue by opposing insulin's anti-lipolytic actions.
- Glucagon stimulates cAMP production, which can activate **hormone-sensitive lipase** to break down triglycerides into **fatty acids** and **glycerol**.
- However, **catecholamines (epinephrine/norepinephrine)** are far more potent direct stimulators of adipose tissue lipolysis than glucagon.
- The friend is attempting to exploit this lipolytic effect for fat loss, though **exogenous glucagon is not an evidence-based or safe weight-loss strategy**.
*Increased glucose utilization by tissues*
- This is **opposite** to glucagon's actual effect. **Glucagon raises blood glucose** levels; it does not promote glucose uptake by peripheral tissues.
- **Insulin** is the hormone responsible for promoting glucose uptake and utilization by muscle, adipose, and other tissues.
*Decreased blood cholesterol level*
- Glucagon does not have a direct, clinically significant effect on reducing blood cholesterol levels.
- While glucagon affects overall lipid metabolism through its catabolic actions, it is not used therapeutically for hypercholesterolemia.
*Increased hepatic gluconeogenesis*
- **Glucagon strongly stimulates hepatic gluconeogenesis**, which is the synthesis of glucose from non-carbohydrate precursors (amino acids, lactate, glycerol) in the liver.
- This action **raises blood glucose** levels and would not directly contribute to fat loss or weight reduction.
- In the context of a low-carbohydrate diet, increased gluconeogenesis would maintain blood glucose but not promote the fat loss the bodybuilder seeks.
*Increased hepatic glycogenolysis*
- **Glucagon is a potent stimulator of hepatic glycogenolysis**, the breakdown of stored liver glycogen into glucose.
- This rapidly increases blood glucose levels during fasting or hypoglycemia.
- However, this does not directly target adipose tissue for fat loss; it mobilizes glucose stores rather than fat stores, so it's not the mechanism relevant to weight loss goals.
Lipid metabolism US Medical PG Question 4: A 57-year-old man presents to his family physician for a checkup. He has had type 2 diabetes mellitus for 13 years, for which he has been taking metformin and vildagliptin. He has smoked 10–15 cigarettes daily for 29 years. Family history is irrelevant. Vital signs include: temperature 36.6°C (97.8°F), blood pressure 152/87 mm Hg and pulse 88/min. Examination reveals moderate abdominal obesity with a body mass index of 32 kg/m². The remainder of the examination is unremarkable. His fasting lipid profile is shown:
Total cholesterol (TC) 280 mg/dL
Low-density lipoprotein (LDL)-cholesterol 210 mg/dL
High-density lipoprotein (HDL)-cholesterol 40 mg/dL
Triglycerides (TGs) 230 mg/dL
Which of the following is the mechanism of action of the best initial therapy for this patient?
- A. Activation of PPAR-alpha
- B. Inhibition of cholesterol absorption
- C. Bile acid sequestration
- D. Inhibition of cholesterol synthesis (Correct Answer)
- E. Inhibition of adipose tissue lipolysis
Lipid metabolism Explanation: ***Inhibition of cholesterol synthesis***
- This patient has multiple risk factors for cardiovascular disease including **type 2 diabetes**, **hypertension**, **smoking**, and significantly **elevated LDL-cholesterol (210 mg/dL)**, making him a candidate for high-intensity statin therapy.
- **Statins** (HMG-CoA reductase inhibitors) are the first-line therapy for such patients as they significantly reduce cardiovascular events by **inhibiting the rate-limiting step in cholesterol synthesis** in the liver.
*Activation of PPAR-alpha*
- This is the mechanism of action of **fibrates** (e.g., fenofibrate, gemfibrozil), which are primarily used to **lower triglycerides** and raise HDL-cholesterol.
- While this patient has elevated triglycerides, his primary lipid abnormality and cardiovascular risk comes from his high LDL-cholesterol, making statins the better initial choice.
*Inhibition of cholesterol absorption*
- This describes the mechanism of action of **ezetimibe**, which selectively inhibits cholesterol absorption at the brush border of the small intestine.
- Ezetimibe is typically used as an add-on therapy if statins alone are insufficient to reach LDL-C goals, or if a patient is statin-intolerant, not as a monotherapy for high-risk patients.
*Bile acid sequestration*
- This is the mechanism of **bile acid resins** (e.g., cholestyramine, colestipol, colesevelam), which bind bile acids in the intestine, preventing their reabsorption and increasing their excretion.
- This leads to increased hepatic synthesis of bile acids from cholesterol, thereby upregulating LDL receptors and lowering LDL-cholesterol, but they are less potent than statins and can cause gastrointestinal side effects.
*Inhibition of adipose tissue lipolysis*
- This is the mechanism of action of **niacin (nicotinic acid)**, which reduces the synthesis of VLDL and LDL by inhibiting lipolysis in adipose tissue.
- Niacin can improve all lipid parameters but is often associated with significant side effects (e.g., flushing, insulin resistance) and has not consistently shown cardiovascular benefit beyond statins in recent trials, making it a less preferred initial therapy.
Lipid metabolism US Medical PG Question 5: A 50-year-old man comes to the physician for his annual health maintenance examination. The patient feels well. He has a history of hypertension, for which he currently takes lisinopril. He has smoked a pack of cigarettes daily for 20 years. He drinks 5–6 beers on weekends. He is 181 cm tall (5 ft 11 in), weighs 80 kg (176.4 lbs); BMI is 24.6 kg/m2. His pulse is 75/min, blood pressure is 140/85 mm Hg, and respirations are 18/min. Physical examination is unremarkable. Laboratory studies show:
Total cholesterol 263 mg/dL
High-density lipoprotein cholesterol 36 mg/dL
Triglycerides 180 mg/dL
In addition to dietary and lifestyle modification, administration of which of the following agents is the most appropriate next step in management?
- A. Peroxisome proliferator-activated receptor alpha activator
- B. Proprotein convertase subtilisin kexin 9 inhibitor
- C. Bile acid resins
- D. HMG-CoA reductase inhibitor (Correct Answer)
- E. Cholesterol absorption inhibitor
Lipid metabolism Explanation: ***HMG-CoA reductase inhibitor***
- This patient has multiple **cardiovascular risk factors** (hypertension, smoking, low HDL, elevated LDL-c calculated from total cholesterol and triglycerides) and elevated LDL-c. An **HMG-CoA reductase inhibitor (statin)** is the first-line pharmacotherapy in such cases to reduce the risk of atherosclerotic cardiovascular disease events.
- Statins effectively lower **LDL-c**, which is the primary target for cholesterol reduction in patients at high risk for cardiovascular disease.
*Peroxisome proliferator-activated receptor alpha activator*
- **Fibrates** (PPAR-α activators) are primarily used to lower **triglycerides** and increase HDL, and are not the first-line choice for lowering elevated LDL-c in high-risk patients.
- They are typically reserved for severe hypertriglyceridemia not controlled by statins, or in patients intolerant to statins whose primary lipid issue is hypertriglyceridemia.
*Proprotein convertase subtilisin kexin 9 inhibitor*
- **PCSK9 inhibitors** are potent LDL-c lowering agents, but they are typically used as **adjunctive therapy** in patients with high cardiovascular risk who have not achieved adequate LDL-c reduction with maximum tolerated statin therapy, or in patients with familial hypercholesterolemia.
- Given that this patient has not yet started statin therapy, a PCSK9 inhibitor is not the initial treatment strategy.
*Bile acid resins*
- **Bile acid resins** (e.g., cholestyramine) lower LDL-c by binding to bile acids in the intestine, but they are **less effective** than statins and can sometimes increase triglycerides.
- They are generally not the first-line choice for primary LDL-c reduction due to their side effect profile (e.g., GI upset) and lower efficacy compared to statins.
*Cholesterol absorption inhibitor*
- **Ezetimibe** (a cholesterol absorption inhibitor) reduces cholesterol absorption in the small intestine, leading to lower LDL-c.
- It is often used as an **add-on therapy** to statins or as monotherapy in statin-intolerant patients, but not as the initial drug of choice when a statin is indicated and tolerated.
More Lipid metabolism US Medical PG questions available in the OnCourse app. Practice MCQs, flashcards, and get detailed explanations.
